It was a yawner IMO. The tweaking of the presentation is something that was long overdue, basically telling investors what’s in it for them versus the clinical/engineering pitch he usually gives to a bunch of money people that don’t really care about that. Q4 milestone by end of year. De Novo route confirmed by FDA. Submission early 2023 and approval late 2023. IDE coming soon with 30+ case human trials at 3-4 centers. Very protected by patents commenting that they precede many other SP RAS in the space. Also mentioned they are one of the few Authentic SP players in the space(paraphrasing). He’s a little too conservative in these presentations IMO. Oh and money to take them to end of 2022.
News 
Market Data 
Discover 
